News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
696,394 Results
Type
Article (39561)
Company Profile (247)
Press Release (656586)
Section
Business (204108)
Career Advice (2007)
Deals (35413)
Drug Delivery (94)
Drug Development (81011)
Employer Resources (172)
FDA (16157)
Job Trends (14844)
News (345058)
Policy (32502)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (5)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2547)
Accelerated approval (4)
Adcomms (20)
Allergies (80)
Alliances (49376)
ALS (83)
Alzheimer's disease (1357)
Antibody-drug conjugate (ADC) (109)
Approvals (16159)
Artificial intelligence (233)
Autoimmune disease (16)
Automation (14)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (18)
Biosimilars (101)
Biotechnology (175)
Bladder cancer (58)
Brain cancer (25)
Breast cancer (252)
Cancer (2016)
Cardiovascular disease (162)
Career advice (1674)
Career pathing (29)
CAR-T (140)
Cell therapy (397)
Cervical cancer (19)
Clinical research (65741)
Collaboration (769)
Compensation (466)
Complete response letters (19)
COVID-19 (2581)
CRISPR (35)
C-suite (211)
Cystic fibrosis (98)
Data (1986)
Decentralized trials (2)
Denatured (16)
Depression (38)
Diabetes (249)
Diagnostics (6337)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (113)
Drug pricing (95)
Drug shortages (25)
Duchenne muscular dystrophy (85)
Earnings (86224)
Editorial (32)
Employer branding (21)
Employer resources (146)
Events (111716)
Executive appointments (649)
FDA (17279)
Featured Employer (47)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (691)
Gene editing (97)
Generative AI (18)
Gene therapy (278)
GLP-1 (685)
Government (4383)
Grass and pollen (4)
Guidances (49)
Healthcare (18810)
Huntington's disease (22)
IgA nephropathy (24)
Immunology and inflammation (103)
Indications (26)
Infectious disease (2713)
Inflammatory bowel disease (132)
Inflation Reduction Act (8)
Influenza (48)
Intellectual property (87)
Interviews (311)
IPO (16486)
IRA (40)
Job creations (3628)
Job search strategy (1422)
Kidney cancer (9)
Labor market (34)
Layoffs (455)
Leadership (16)
Legal (7901)
Liver cancer (70)
Lung cancer (293)
Lymphoma (134)
Machine learning (4)
Management (58)
Manufacturing (268)
MASH (61)
Medical device (13327)
Medtech (13332)
Mergers & acquisitions (19408)
Metabolic disorders (632)
Multiple sclerosis (72)
NASH (16)
Neurodegenerative disease (80)
Neuropsychiatric disorders (24)
Neuroscience (1841)
NextGen: Class of 2025 (6512)
Non-profit (4476)
Northern California (2458)
Now hiring (37)
Obesity (340)
Opinion (201)
Ovarian cancer (72)
Pain (78)
Pancreatic cancer (76)
Parkinson's disease (138)
Partnered (20)
Patents (204)
Patient recruitment (97)
Peanut (46)
People (57106)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20472)
Phase II (28948)
Phase III (21580)
Pipeline (1057)
Podcasts (45)
Policy (114)
Postmarket research (2563)
Preclinical (8658)
Press Release (64)
Prostate cancer (94)
Psychedelics (30)
Radiopharmaceuticals (244)
Rare diseases (359)
Real estate (5901)
Recruiting (65)
Regulatory (22156)
Reports (46)
Research institute (2318)
Resumes & cover letters (349)
Rett syndrome (4)
RNA editing (4)
RSV (39)
Schizophrenia (64)
Series A (121)
Series B (78)
Service/supplier (11)
Sickle cell disease (51)
Southern California (2118)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (28)
Startups (3571)
State (2)
Stomach cancer (13)
Supply chain (60)
Tariffs (11)
The Weekly (27)
United States (21328)
Vaccines (657)
Venture capitalists (37)
Webinars (12)
Weight loss (224)
Women's health (33)
Worklife (15)
Date
Today (16)
Last 7 days (653)
Last 30 days (2531)
Last 365 days (33359)
2025 (8275)
2024 (35221)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54086)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29264)
2010 (27329)
Location
Africa (718)
Alabama (49)
Alaska (7)
Arizona (224)
Arkansas (13)
Asia (37711)
Australia (6167)
California (5582)
Canada (1880)
China (476)
Colorado (247)
Connecticut (256)
Delaware (128)
Europe (80879)
Florida (828)
Georgia (196)
Idaho (57)
Illinois (500)
India (24)
Indiana (292)
Iowa (9)
Japan (143)
Kansas (101)
Kentucky (23)
Louisiana (9)
Maine (61)
Maryland (834)
Massachusetts (4195)
Michigan (209)
Minnesota (371)
Mississippi (2)
Missouri (77)
Montana (27)
Nebraska (25)
Nevada (56)
New Hampshire (62)
New Jersey (1592)
New Mexico (28)
New York (1603)
North Carolina (922)
North Dakota (7)
Northern California (2458)
Ohio (192)
Oklahoma (14)
Oregon (33)
Pennsylvania (1264)
Puerto Rico (9)
Rhode Island (27)
South America (1094)
South Carolina (18)
South Dakota (1)
Southern California (2118)
Tennessee (95)
Texas (832)
Utah (164)
Virginia (130)
Washington D.C. (57)
Washington State (516)
West Virginia (3)
Wisconsin (49)
696,394 Results for "gtx inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
February 10, 2025
·
10 min read
Drug Development
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
Ultragenyx Pharmaceutical Inc. announced new data from the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome.
April 15, 2024
·
12 min read
Business
Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX
Halberd Corporation is thrilled to declare the formalization of a profitable revenue-sharing accord with Athena GTX, Inc., of Johnston, Iowa,. Athena GTX is a private enterprise specializing in providing medical care solutions tailored for first responders in both civilian and government sectors.
January 9, 2024
·
5 min read
Press Releases
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
December 19, 2024
·
7 min read
Biotech Bay
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the conference call to discuss new clinical efficacy and safety data from the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome that will be presented at the American Academy of Neurology Meeting (AAN), will now be taking place on Monday, April 15, 2024 at 8 a.m. Eastern Time (ET).
April 12, 2024
·
1 min read
Biotech Bay
Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to GTX-102 for the treatment of Angelman syndrome (AS).
February 5, 2024
·
7 min read
Drug Development
Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome
Ultragenyx Pharmaceutical Inc. today announced the completion of patient enrollment in its Phase 1/2 clinical trial of GTX-102 for the treatment of pediatric patients with Angelman syndrome (AS).
January 3, 2024
·
6 min read
Press Releases
Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024
October 30, 2024
·
10 min read
Press Releases
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
November 11, 2024
·
8 min read
Press Releases
Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104
September 26, 2024
·
7 min read
1 of 69,640
Next
